Ahead of PTC Therapeutics (PTCT) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Core Insights - Wall Street analysts anticipate PTC Therapeutics (PTCT) will report a quarterly loss of -$0.21 per share, reflecting a year-over-year increase of 12.5% [1] - Expected revenues for the quarter are $304.72 million, representing a 42.9% increase from the same quarter last year [1] - The consensus EPS estimate has been revised upward by 15.3% over the past 30 days, indicating a collective reassessment by analysts [1] Revenue Estimates - Analysts predict 'Revenues- Net product revenue' will reach $174.53 million, showing a year-over-year change of +12.8% [4] - 'Revenues- Royalty revenue' is estimated to be $70.77 million, indicating a change of +21.7% from the prior-year quarter [4] - The estimated 'Revenues- Net product revenue- Translarna' is projected at $40.42 million, reflecting a significant decline of -56.9% from the prior-year quarter [4] - 'Revenues- Net product revenue- Emflaza' is expected to be $29.58 million, indicating a decrease of -41.4% from the prior-year quarter [5] Stock Performance - Over the past month, PTC Therapeutics shares have declined by -4.2%, compared to a -1.7% change in the Zacks S&P 500 composite [5] - The company holds a Zacks Rank 3 (Hold), suggesting that its performance is likely to align with the overall market in the near term [5]